Ocaratuzumab is a monoclonal antibody designed for therapeutic use, primarily targeting the CD20 antigen found on the surface of B cells. This characteristic makes it particularly relevant in the treatment of certain hematological malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. As a humanized IgG1 antibody, Ocaratuzumab is engineered to enhance its efficacy and reduce immunogenicity compared to murine antibodies. Its mechanism of action involves binding to CD20, leading to the destruction of B cells through various immune-mediated processes, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The development of Ocaratuzumab reflects advancements in targeted therapies, aiming to improve patient outcomes while minimizing side effects associated with traditional chemotherapy. Clinical studies have been conducted to evaluate its safety, efficacy, and optimal dosing regimens, contributing to the growing arsenal of biologic therapies in oncology. As with any therapeutic agent, ongoing research continues to refine its applications and understand its long-term effects in diverse patient populations.

Ocaratuzumab

1169956-08-4: Ocaratuzumab is a monoclonal antibody designed for therapeutic use, primarily targeting the CD20 antigen found on the surface of B cells. This characteristic makes it particularly relevant in the treatment of certain hematological malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. As a humanized IgG1 antibody, Ocaratuzumab is engineered to enhance its efficacy and reduce immunogenicity compared to murine antibodies. Its mechanism of action involves binding to CD20, leading to the destruction of B cells through various immune-mediated processes, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The development of Ocaratuzumab reflects advancements in targeted therapies, aiming to improve patient outcomes while minimizing side effects associated with traditional chemotherapy. Clinical studies have been conducted to evaluate its safety, efficacy, and optimal dosing regimens, contributing to the growing arsenal of biologic therapies in oncology. As with any therapeutic agent, ongoing research continues to refine its applications and understand its long-term effects in diverse patient populations.

Anti-CD20 humanized monoclonal antibody; designed for cancer and autoimmune disorders treatment

Ocaratuzumab (AME-133v) is an Fc-engineered antibody and humanized monoclonal antibody targeting CD20 (Kd≈100 pM), exhibiting ADCC in leukemia.

CAS 1169956-08-4

Ocaratuzumab

Ocaratuzumab

Ref: 3D-CLA1308

Ocaratuzumab

Ref: TM-T76821